Prof. Dr. Arif Al Nooryani: “We are very pleased with the success of the Ultra Low Contrast PCI project at Al Qassimi Hospital, which will certainly benefit physicians and patients. We aim to have a long-term close partnership with Philips to develop ULC- PCI Educational Program.”
“Following the successful launch of our ULC-PCI training at EuroPCR in 2022 and the impressive results our clinical partners have achieved over the past year in treating vulnerable CAD patients, we are delighted that Al Qassimi Hospital is spearheading this Training programs to spread their expertise to doctors from the Middle East, Turkey, Africa and Europe”, said Dr Atul Gupta, Chief Medical Officer, Image-Guided Therapy, Philips.
By minimizing the amount of iodine contrast that needs to be injected into a patient’s arteries to visualize them on x-ray images, the ultra-low contrast PCI procedure opens up the possibility of using a minimally invasive procedure to treat coronary heart disease (CHD) in patients whose kidneys cannot cope with contrast in patients with dose toxicity. This includes frail and elderly patients as well as patients with chronic kidney disease (CKD). The benefits are especially important for patients with both CKD and CAD (coronary artery disease), as the two conditions tend to aggravate each other. Treating their heart disease can help their kidneys recover or slow the rate at which their kidneys decline, dramatically improving their quality of life.